MedCity News December 9, 2025
YaoPharma’s once-daily oral GLP-1 drug is currently in Phase 1 testing. The license agreement gives Pfizer global rights to the small molecule, which it envisions as part of potential drug combinations.
Fresh off the acquisition of metabolic medicines developer Metsera, Pfizer is again turning to dealmaking to expand its obesity drug pipeline, this time picking up an experimental oral drug that could become part of combinations with other assets in the pharmaceutical giant’s pipeline.
The drug, YP05002, comes from YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical. Per deal terms announced Tuesday, Pfizer will pay $150 million up front for global rights to the asset, which is currently in early clinical development.
YP05002 is an oral small molecule designed to activate...
Today's Sponsors
Today's Sponsor